No Data
The rebound also functions with the 200-day line as a support.
The Nikkei average rebounded. It closed the trading at 38,414.43 yen, up 193.58 yen (approximately 1.8 billion shares in volume), following the trend in the US market. It started with a rebound, recovering the milestone of 38,500 yen just after the opening. However, active buying was limited, and there were scenes where the price increase narrowed to 38,246.36 yen in the mid-morning session. Subsequently, although the market development was characterized by a stalemate, there were also moments in the afternoon session when the price briefly exceeded the high of 38,560.10 yen set in the morning.
The Nikkei average has rebounded and is fluctuating slightly while waiting for nvidia's earnings report.
On the 18th, the USA market was mixed. The Dow Jones Industrial Average closed the trading session at 43,389.60, down 55.39 points, while the NASDAQ ended at 18,791.81, up 111.69 points. With limited news at the opening, the market was mixed. The unexpected improvement in the November NAHB Housing Market Index and strong growth expectations provided support, but the Dow was pressured by profit-taking sales and traded weakly throughout the day. The NASDAQ was supported by the rise of electric car maker Tesla, a decline in long-term interest rates, and expectations for the earnings of semiconductor company NVIDIA.
Chordia---a biotech venture advancing the development of anticancer drugs that could become block inc.
Chordia Therapeutics <190A> is a biotech venture founded by drug discovery researchers who spun out from takeda pharmaceuticals sp adr <4502>, specializing in the development of low molecular weight anti-cancer drugs. The core business ranges from exploratory research to clinical research, and domestically, it conducts manufacturing and sales on its own through a partnership strategy, aiming for early monetization by licensing out overseas. It was listed on the Tokyo Stock Exchange Growth Market in June 2024.
GRAIL Announces The First Patient Has Been Tested For Eligibility With Its Non-Small Cell Lung Cancer CtDNA Assay In The TROPION-Lung12 Phase 3 Study, Sponsored By AstraZeneca In Collaboration With Daiichi Sankyo
High-tech stocks and pharmaceutical stocks are a burden on the market.
The Nikkei average plunged significantly, closing at 38,220.85 yen, down 422.06 yen (trading volume approximately 1.73 billion shares). Reflecting the decline in semiconductor-related sectors in the US market last week, selling pressure focused on tech stocks also dominated the Tokyo market. The Nikkei average dropped to 38,150.39 yen shortly after the opening of trading. However, spurred by comments from BOJ Governor Kuroda at a morning speech, the yen temporarily weakened to the 155 yen range against the dollar, leading to increased buying activity in futures and other markets.
The Nikkei average fell significantly, weighed down by the decline in tech stocks.
Last weekend, the Dow Jones Industrial Average in the USA market closed with a loss of 305.87 points at 43444.99 points, while the NASDAQ closed with a loss of 427.53 points at 18680.12 points. The selling pressure continued following hawkish remarks by Federal Reserve Chair Powell, leading to a decline after the opening. Buying interest, which was driven by expectations of policies supporting corporate performance such as deregulation by the upcoming Trump administration, paused. Furthermore, the speculation of an additional rate cut in December receded after comments from Fed officials, contributing to the continued decline. US stocks that declined.